IQ GENETIC TECHNOLOGY LIMITED × HKRM Lab Joint Product
IQ GENETIC × HKRM Joint Product · PIC/S GMP Certified

Stem Cell Exosomes Protecting YourLung Health
with Science

Designed for Pulmonary Nodules · Pulmonary Fibrosis · Lung Function Restoration

N
Tsinghua University Clinical · Published in Nature
Signal Transduction and Targeted Therapy · 24 patients · Zero severe adverse events · FVC improved +12.5% on average
🫁

JuvGuard

Stem Cell Exosome

450+
Active Growth Factors
83.3%
Clinical Response Rate
24
临床患者
83.3
%
有效率
+12.5
%
FVC提升
0
不良反应
450
+种
生长因子
80
%
生存率提升
Signal Transduction and Targeted Therapy
Top Nature Journal · IF 39.3

World's First Inhaled Stem Cell Exosome
Clinical Trial for Pulmonary Fibrosis

HKRM Laboratory
24 Enrolled Patients
Published 2025
Read Full Research Report
+12.5%
Average FVC (forced vital capacity) improvement
7Days
Days to significant lung function improvement
79Yrs
Oldest patient tolerated well (elderly-friendly)
2080%
Survival rate improvement in animal model (bleomycin)

Why Choose JuvGuard

Exosomes derived from umbilical cord mesenchymal stem cells, carrying 450+ active factors, delivered directly to the lungs via nebulization

🎯

Precision Targeting

CXCR4 receptors on exosome surface identify lung lesions, actively accumulating in damaged areas with no systemic toxicity.

CXCR4 Guided Lung-Targeted Zero Systemic Toxicity
🛡️

Anti-inflammatory Regulation

Suppresses TNF-α, IL-6, IL-1β and other pro-inflammatory factors; induces macrophage M1→M2 polarization, breaking the chronic inflammation cycle.

Anti-inflammatory Immune Modulation Macrophage Shift
🔬

Tissue Repair & Regeneration

Carries HGF, EGF, FGF, VEGF and 450+ growth factors, stimulating alveolar epithelial cell proliferation and repairing damaged alveolar structures.

HGF/EGF Alveolar Regen. 450+ Factors
💊

Anti-fibrotic Reversal

Downregulates TGF-β expression, reduces excessive collagen deposition, halts "scarring" progression and reverses established fibrotic lesions.

TGF-β Inhibition Anti-fibrotic Reversible

GMP-Grade Quality

PIC/S GMP certified + A/B grade sterile production. Animal-origin-free (AOF) culture medium ensures absolute safety and purity.

PIC/S GMP Sterile Mfg. AOF Culture
🌬️

Non-invasive Nebulization

Inhaled via nebulizer in 10–15 minutes, painless and non-invasive, reaching deep lung tissue. Suitable for elderly patients; no injection required.

Non-invasive Home Use Elderly Friendly

4 Steps to Reverse Lung Disease

After nebulized inhalation, exosomes repair the lungs through four core mechanisms

1

Inhaled · Reaches Lesions

Nano-scale exosomes (30–150 nm) are aerosolized by a nebulizer, penetrating deep into alveoli and targeting inflamed/fibrotic lesion zones.

2

Anti-inflammation · Removes Cause

Releases miRNA-21, miRNA-146a and other regulatory molecules, suppressing the NF-κB inflammatory pathway and resolving chronic lung inflammation at the source.

3

Factor Release · Activates Repair

HGF, EGF, VEGF and 450+ growth factors act on damaged cells, activating Type II alveolar epithelial proliferation and rebuilding alveolar structures.

4

Anti-fibrosis · Reverses Disease

TGF-β signaling is potently inhibited, excessive collagen deposition is reduced, established fibrotic lesions gradually dissolve — visible regression on HRCT.

Human Umbilical Cord MSC-Derived Exosomes

hUCMSC-EVs · Nano-scale Cell Vesicles
Diameter 30–150 nm

HGF Hepatocyte GF EGF Epidermal GF VEGF Vascular Endothelial GF FGF Fibroblast GF TIMP1 Metalloprotease Inhibitor miRNA-21/146a +450 Active Factors
≥100B
Particles/mL
120B
Exosomes per Course

Documented Clinical Improvements

Real patient data from clinical reports, each case with before/after CT imaging comparison

👩 Female · 42 yrs
Left lower lobe · 8mm GGO · No response to anti-inflammatory for 3 months
Fully Resolved
17 Days
Day 0: 8mm ground-glass opacity, margins visible
Day 6: Density markedly reduced, shrunk to 5mm
Day 17: Lesion fully absorbed, no fibrotic residue
👨 Male · 56 yrs
Post-COVID · 5 bilateral GGOs · largest 10mm
Mostly Resolved
34 Days
Day 0: 5 bilateral GGOs, largest 10mm
Day 20: Most nodules absorbed, largest shrunk to 4mm
Day 34: Bilateral lesions mostly resolved, faint strand residue only
👨 Male · 55 yrs · 20yr smoker
Right upper lobe · 12mm mixed GGO
Reduced 70%
2 Months
Day 0: 12mm mixed nodule, solid component ~6mm
Day 30: Shrunk to 8mm, solid portion reduced, GGO faded
Day 60: Shrunk to 3.5mm, density near normal lung tissue
👵 Female · 68 yrs
Chronic bronchitis · 6 bilateral nodules 3–5mm · recurrent cough
All Resolved
3 Months
Before: 6 scattered bilateral nodules, cough & dyspnea
3 Months: All 6 nodules absorbed, clear pulmonary markings
FEV1: +15% improvement, SpO₂ from 92% to 97%

Institutional Partners & Support

HKRM Laboratory
BMS-Certified Stem Cell Center, Japan

Frontier Science · Clinical Progress

Tracking the latest research and clinical advances in stem cell exosome therapy

📊 科研资讯
清华团队突破!!雾化吸入干细胞外泌体,7天逆转肺纤维化进程,24例临床数据登顶《Nature》子刊

清华大学基础医学院常智杰教授团队联合解放军总医院等单位,在国际顶尖期刊Signal Transduction and Targeted Therapy(Nature子刊)发表重磅研究成果,证实雾化吸入人脐带间充质干细胞外泌体(hUCMSC-EVs)可安全、有效逆转肺纤维化。

🩺 临床案例
孤立性磨玻璃结节,17天完全吸收——干细胞外泌体雾化真实案例

42岁女性患者,左肺下叶外基底段孤立磨玻璃结节(直径约8mm),抗炎治疗3个月无效后,采用脐带间充质干细胞外泌体雾化治疗,17天后病灶完全吸收。

🔬 科研资讯
常智杰课题组开发肺纤维化治疗新方法并完成I期临床试验

清华大学医学院常智杰课题组开发了利用脐带来源间充质干细胞的细胞外囊泡(外泌体)雾化吸入治疗肺纤维化的方法,并完成了全球首个该领域的I期临床试验。

Start Your Lung Health Journey

Our expert team provides personalized consultation plans, grounded in Nature clinical research, to scientifically protect your lung health

Consult